We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




CRISPR-based Technology Enables High-Resolution Zika Detection On Low-Cost Paper Discs

By LabMedica International staff writers
Posted on 16 May 2016
Building off their earlier innovative development in “programmable diagnostics”, researchers on an international, multi-institutional team recently joined efforts to quickly prototype their low-cost rapid test with the goal that it could soon be used to screen samples (blood, urine, or saliva) for Zika virus and strain identification.

The team, led by synthetic biologist Prof. More...
James Collins, Wyss Institute for Biologically Inspired Engineering at Harvard University (Boston, MA, USA) and Massachusetts Institute of Technology (USA), has developed the paper-based system for strain-specific detection as an inexpensive method to help slow the spread of Zika outbreak, and potentially of other future pandemic diseases.

"The growing global health crisis caused by the Zika virus propelled us to leverage novel technologies we have developed in the lab and use them to create a workflow that could diagnose a patient with Zika, in the field, within 2-3 hours," said Prof. Collins. "We hope a tool like this can help reduce the impact of the outbreak until a vaccine can be developed," said co-first author Dr. Keith Pardee, University of Toronto (Canada).

In 2014, the team developed a breakthrough method for embedding synthetic gene networks— which could be used as programmable diagnostics and sensors – on small paper discs. Stirred by the then-ongoing Ebola outbreak in Africa, they demonstrated a proof-of-concept color-changing diagnostic that could screen for Ebola by embedding in paper a novel kind of synthetic biomolecular sensor designed to screen for specific RNA sequences, which could mark not only genetic signatures of Ebola but also other RNA viruses (e.g. Zika, SARS, measles, influenza, hepatitis C, West Nile fever).

A major challenge was the extremely low concentration of virus normally found in blood, urine, and saliva. Now, using blood samples from monkeys infected with Zika virus as well as virus recovered from cells infected in the laboratory, the team has validated a next-generation technique that overcomes this problem.

With field-use in mind, the team designed a simple modular workflow comprising 3 steps: amplification, Zika detection, and CRISPR-aided strain identification. Once a sample’s RNA has been amplified, it is added onto freeze-dried paper discs containing biomolecular components. The droplet of amplified RNA activates the freeze-dried components so that the discs will change color to indicate a positive result for Zika virus. While the result can be read with the naked eye similar to a home pregnancy test, a specially designed electronic reader can also be used to get faster results and could, one day, quantify the amount of viral load in a sample.

If Zika is detected, the third step involves mixing a sample with a freeze-dried CRISPR (i.e. CRISPR-Cas9) cocktail and then using that mixture to wet another set of color-changing paper discs. Depending on the type of Zika strain in the sample, these discs undergo another set of visible color changes. Leveraging CRISPR’s talent for sequence recognition, this third step enables discriminate between strains whose genetic profiles differ by as little as one nucleotide – providing single-base resolution.

Although synthetic biologists and genetic engineers usually put CRISPR to work inside living cells, the team discovered that it functions just as well - and even better in some cases - when freeze -dried.

"We have tested our diagnostic systems against closely-related strains of the Dengue virus and found that within the first two steps, our system can readily distinguish Zika from Dengue," said co-first author Prof. Alexander Green, PhD, Arizona State University (USA), "Addition of the third CRISPR-based step — deploying Cas9 on a paper-based platform for the first time — only enhances the accuracy of detection. As we prepare this technology for translation, we plan to validate our system against dozens or even hundreds of clinical samples."

The ability to pinpoint a strain-specific diagnosis in the field could prove valuable to national and global health organizations for tracking the spread of a viral outbreak in real-time and for preparing containment strategies and treatment plans.

The cost-effective diagnostic platform could be tailored to identify a range of pathogens. What’s more — the method is robust and could be used to quickly respond and develop new diagnostics: "In response to an emerging outbreak, we envision a custom-tailored diagnostic system could be ready for use within one week’s time," said Prof. Collins, "We are currently pursuing multiple opportunities to secure private and public funding in order to commercialize this diagnostic system and make it available to the world’s health responders."

"The ability to recapitulate the genetic machinery of living cells in ordinary freeze-dried paper provides a way to develop revolutionary sensors and diagnostics in a fraction of the time and with higher sensitivity and specificity than more conventional assays," said Wyss Institute founding director Prof. Donald Ingber, MD, PhD.

The study, by Pardee, Green, Takahashi, Braff, Lambert et al, was published May 6, 2016, in the journal Cell.

Related Links:
Wyss Institute for Biologically Inspired Engineering at Harvard University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Manual Pipetting Aid
Pipette Controllers macro
Automated Clinical Chemistry Analyzer
Envoy 500+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: GRAIL’s Galleri test uses machine learning to analyze cfDNA patterns for cancer signals and predict their likely location to guide further evaluation.

Multi-Cancer Blood Test Expands Detection to Cancers Lacking Routine Screening Options

Many lethal cancers lack routine screening and are often diagnosed only after symptoms emerge, limiting curative options. Standard programs in the United States cover a small subset of malignancies, leaving... Read more

Molecular Diagnostics

view channel
Image: MPNST is a cancer of the connective tissue surrounding peripheral nerves, with NF1 being a key risk factor (Image Credit: Nephron/Wikimedia Commons (CC BY-SA 3.0)

Liquid Biopsy Shows Promise for Detecting and Monitoring Malignant Nerve Sheath Tumors

Malignant peripheral nerve sheath tumor (MPNST) is one of the most serious cancers affecting people with neurofibromatosis type 1 (NF1), yet timely recognition remains difficult. Clinicians often struggle... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.